Sovaldi(Sofosbuvir)Tablets-Million Health Pharmaceuticals
The following indications for sofosbuvir relate to patients with chronic hepatitis C virus infection. Sofosbuvir is indicated for treatment of patients with chronic HCV
Genotype 1 or 4: sofosbuvir plus peginterferon-alfa plus ribavirin for 12 weeks
Genotype 2: sofosbuvir plus ribavirin for 12 weeks
Genotype 3: sofosbuvir plus ribavirin for 24 weeks
For the treatment of patients with HCV-HIV-1 coinfection: the recommendations are the same as listed above. For patents with genotype 1 HCV who are not eligible to receive interferon: sofosbuvir plus ribavirin for 24 weeks can be considered.
Sofosbuvir 400 mg Tablets (Sovaldi)used to treat Chronic HCV.